Mutual of America Capital Management’s Cogent Biosciences COGT Stock Holding History

Mutual of America Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.1M	Buy	+106,044	New	+$3.71M	0.04%	509

Other funds holding COGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Mutual of America Capital Management's COGT Position: Q2 2026 in Review

Mutual of America Capital Management opened a new position in Cogent Biosciences (COGT) in Q2 2026: 106,044 shares worth $4.1M. The stake represents 0.04% of the portfolio and ranks #509 among its holdings.

125 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Mutual of America Capital Management held 106,044 shares of Cogent Biosciences worth $4.1M as of Q2 2026.
Cogent Biosciences was a new Mutual of America Capital Management position in Q2 2026.
Cogent Biosciences made up 0.04% of Mutual of America Capital Management's portfolio in Q2 2026, its #509 holding.
125 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Mutual of America Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.